This article is more than 5 years old. Information may no longer be current.
Rebiotix announces US patent for microbiota restoration therapy
Click Here to Manage Email Alerts
Rebiotix announced that, in addition to its Australian and Canadian patents, it has received a U.S. patent covering its microbiota restoration therapy compositions and related manufacturing, processing and delivery methods.
“This patent covering our [microbiota restoration therapy] platform is a significant addition to Rebiotix’s IP estate as we continue to advance our industry-leading pipeline of microbiome-directed drug therapies, including RBX2660, our phase 3-ready drug candidate,” Lee Jones, CEO of Rebiotix, said in a press release. “Rebiotix has established one of the deepest IP portfolios in the microbiome industry covering an array of subjects, from formulation and storage to delivery and disease targets, that we believe are key to the eventual commercialization of microbiota-based therapeutics.”
The company’s development pipeline is built around its microbiota restoration therapy platform, which is “a standardized, stabilized drug technology” that delivers a broad spectrum of live microbes to the intestinal tract, with the goal of rehabilitating the microbiome to treat diseases like Clostridium difficile infection, ulcerative colitis, hepatic encephalopathy and multi-drug resistant organisms, according to the press release.
Disclosures: Jones is employed by Rebiotix.